Expression of erbB receptors and their ligands in breast cancer: Implications to biological behavior and therapeutic response

Breast Disease

Volumn 11, Issue , 2000, Pages 63-75

  Bacus, Sarah S ^a,b,c,d   Gudkov, Andrei V ^a,b,c,d   Esteva, Francisco J ^a,b,c,d   Yarden, Yosef ^a,b,c,d  

^a Quantitative Diagnostics Laboratory   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BIOLOGICAL MARKER; CISPLATIN DERIVATIVE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; FLUOROURACIL; LIGAND; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PACLITAXEL; PHENYLALANINE; PROGESTERONE; PROTEIN TYROSINE KINASE; TAMOXIFEN; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0033890970     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-1999-11106     Document Type: Article

References (95)

1. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
2. Drug therapy: Treatment of breast cancer
3. In vitro determination of drug response: A discussion of clinical applications
4. How to use prognostic factors in axillary node-negative breast cancer patients
5. Application of quantitative analysis to biologic profile evaluation in breast cancer
6. National Institute of Health Consensus Development Conference
7. Overexpression of a transporter gene in a multi-drug resistant human lung cancer cell line
8. Multidrug resistance
9. Molecular mechanism and diagnostics of multidrug resistance in human tumor cells
10. Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers
11. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients
12. Overexpression of p53 in human breast cancer
13. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer
14. Expression of p53 and bcl-2 in correlation to clinicopathological parameters, hormone receptor status and DNA ploidy in breast cancers
15. Balancing cell life and death: Bax, apoptosis and breast cancer
16. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
17. Prognostic value of p21 WAF1 and p53 expression in breast carcinoma: An immunohistochemical study in 261 patients with long-term follow-up
18. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
19. Alterations to either erbB-2 (Neu) or c-myc protooncogenes in breast carcinomas correlate with poor short-term prognosis
20. Studies of the HER2/neu protooncogene in human breast and ovarian cancer
21. Neuprotein overexpression in breast cancer: Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer
22. Pathological findings from national surgical adjuvant breast project (protocol B-06): Prognostic significance of erbB-2 protein overexpression in primary breast cancer
23. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo
24. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: Immunohistological assessment correlated with gene amplification
25. Association of c-erb-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer
26. Infiltrating carcinoma: Major histological types
27. Signal transduction by receptors with tyrosine kinase activity
28. Growth factor receptor tyrosine kinases
29. Growth factors and cancer
30. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors
31. A v-erbB-2 related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma
32. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with the neu oncogene
33. The neu oncogene encodes an epidermal growth factor receptor-related protein
34. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor
35. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH-3T3 cells
36. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
37. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment
38. Elevated serum C-erbB antigen levels and decreased response to hormone therapy of breast cancer
39. Expression of epidermal growth factor receptor and C-erbB-2 during the development of tamoxifen resistance in human breast cancer
40. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the Her2/c-neu protein
41. P53 and c-erbB-2 as markers of resistance to adjuvant chemotherapy in breast cancer
42. C-erbB-2 expression predicts tamoxifen efficacy in breast cancer patients
43. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function
44. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both erbB-2 and epidermal growth factor receptors
45. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
46. ErbB-2 is a common signaling subunit of NDF- and EGF-receptors: Implications for breast cancer
47. Epidermal growth factor receptors on human breast cancers
48. Isolation of the neu/Her2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells
49. Heregulin induces tyrosine phosphorylation of HER4/p180 erbB-4
50. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors for all the differentiation/heregulin isoforms
51. C-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer
52. Expression of ras. p21, p53 and C-erbB-2 in advanced breast cancer and response to hormonal therapy
53. Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis
54. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells
55. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors
56. Medullary carcinoma is associated with expression of intercellular adhesion melecule-1
57. Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure
58. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
59. C-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases
60. HER2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A southwest oncology group study
61. Lack of interaction of tamoxifen use and erbB-2/HER2/neu expression in CALGB 8541: A randomized adjuvant trial of three different doses of cyclophosphamide, doxorubicin and fluorouraci in node-positive primary breast cancer
62. HER2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
63. ERBB-2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
64. 20 year update of the Naples gun trial of adjuvant breast cancer therapy: Evidence of interaction between c-erbB-2 expression and tamoxifen efficacy
65. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers
66. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
67. Expression of the c-Ha-ras oncogene in mousr 3T3 cells induces resistance to cisplatin
68. Resistance to anticancer drugs in NIH3 cells transferred with c-myc and/or c-H-ras genes
69. Increased epidermal growth factor receptor in an estrogen-responsive, Adriamycin-resistant MCF-7 cell line
70. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
71. Epidermal growth factor receptor in human breast carcinoma cells: A potential selective target for transforming growth factor α-Psudomonas exotoxin 40 fusion protein
72. Prognostic importance of c-erbB-2 expression in breast cancer
73. c-erbB-2 Expression and response to adjuvant therapy in women with node-positive early breast cancer
74. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
75. Taxol-induced by-totoxicity: Apoptotic signaling via MAP kinase pathways
76. HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications
77. The effect of HER2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
78. Overexpression of both p185 c-erbB-2 and p170 mdr-1 renders breast cancer cells highly resistant to taxol
79. Cancer statistics
80. Antibody to Her2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
81. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cisdiamminedichloroplatinum against human breast and ovarian tumor cell lines
82. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway
83. Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells
84. Phase II study of intravenous recombinant humanized anti-p185 HER2 monoclonal antibody plus cisplatin in patients with HER2/neu overexpressing metastatic breast cancer
85. Phase II study of weekly intravenous recombinant humanized anti-p185(HER2) monoclonal antibody in patients with HER2/neu over-expressing metastatic breast cancer
86. Addition of Herceptin(TM) humanized anti-HER2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer (Her2 +/MBC) markedly increased anticancer activity: A randomized multinational controlled phase II trial
87. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
88. Weekly Herceptin +1 hour Taxol: Phase II study in HER2 overexpressing and non-overexpressing metastatic breast cancer
89. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody herceptin in HER2 overexpressing metastatic breast cancer
90. Neuregulins promote survival and growth of cardiac myocytes
91. Inhibitory effects of combinations of Her2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
92. Topoisomerase II alpha co-amplification with erbB-2 in human primary breast cancer and breast cancer cell lines: Relationship to m-AMSA and mitoxantrone sensitivity